Want to see IRON full AI Analyst Report?
Top Page
Disc Medicine
(NASDAQ:IRON)
Select Model
Select Model
Rating:50Neutral
Price Target:
$75.00
▲(4.50% Upside)
Action:Reiterated
Date:06/30/26
The score is primarily held back by weak financial performance (no revenue, widening losses, and increasing cash burn), partially offset by a comparatively solid equity-funded balance sheet and modestly positive financing/governance events. Technical and valuation inputs are limited or not meaningful due to missing indicators and a negative P/E.
Positive Factors
Balance sheet strength
A sizable equity base (~$688M) and very low leverage provide durable funding capacity to support multi-year clinical programs. This improves the company’s ability to finance R&D, absorb trial setbacks, and negotiate partnerships without immediate refinancing pressure.
Negative Factors
High cash burn
Sustained annual cash burn exceeding $200M creates persistent financing dependence and raises dilution risk if capital raises are required. High burn constrains optionality, forcing prioritization of programs and making long-term execution contingent on continued access to capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
A sizable equity base (~$688M) and very low leverage provide durable funding capacity to support multi-year clinical programs. This improves the company’s ability to finance R&D, absorb trial setbacks, and negotiate partnerships without immediate refinancing pressure.
Read all positive factors
Disc Medicine (IRON) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.93B
Dividend YieldN/A
Average Volume (3M)697.32K
Price to Earnings (P/E)―
Beta (1Y)1.58
Revenue GrowthN/A
EPS Growth-68.57%
CountryUS
Employees94
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.64
Shares Outstanding38,199,090
10 Day Avg. Volume790,528
30 Day Avg. Volume697,324
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-15.46
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.91K
Enterprise Value/Ebitda-11.01
Forecast
1Y Price Target
$101.50Price Target Upside41.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-6.94
Revenue Forecast (FY)N/A
Disc Medicine Business Overview & Revenue Model
Company Description
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from se...
How the Company Makes Money
Disc Medicine is a clinical-stage biopharmaceutical company and, based on publicly available information, does not have recurring commercial product revenue. Its funding and revenue, when present, are typically derived from (1) collaboration, lice...
Disc Medicine Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -176.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -238.25M | -207.94M | -108.27M | -76.23M | -46.74M | -33.78M |
| Net Income | -241.60M | -212.18M | -109.36M | -76.43M | -46.83M | -35.97M |
Balance Sheet | ||||||
| Total Assets | 750.21M | 806.88M | 496.77M | 368.00M | 200.21M | 92.41M |
| Cash, Cash Equivalents and Short-Term Investments | 730.16M | 791.15M | 489.88M | 360.38M | 194.61M | 88.04M |
| Total Debt | 31.06M | 1.86M | 30.00M | 2.10M | 1.33M | 7.06M |
| Total Liabilities | 61.78M | 67.05M | 53.19M | 22.88M | 23.61M | 156.61M |
| Stockholders Equity | 688.43M | 739.83M | 443.59M | 345.12M | 176.60M | -64.20M |
Cash Flow | ||||||
| Free Cash Flow | -201.34M | -181.33M | -94.43M | -73.55M | -42.40M | -27.60M |
| Operating Cash Flow | -201.25M | -180.39M | -93.93M | -73.46M | -42.25M | -27.53M |
| Investing Cash Flow | -63.36M | -394.30M | -292.33M | -89.00K | -151.00K | -68.00K |
| Financing Cash Flow | 230.85M | 473.41M | 218.31M | 239.38M | 148.98M | 89.93M |
Disc Medicine Technical Analysis
Positive
71.77
Price Trends
70.15
Positive
67.43
Positive
74.14
Positive
Market Momentum
2.55
Negative
59.75
Neutral
66.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRON, the sentiment is Positive. The current price of 71.77 is below the 20-day moving average (MA) of 73.24, above the 50-day MA of 70.15, and below the 200-day MA of 74.14, indicating a bullish trend. The MACD of 2.55 indicates Negative momentum. The RSI at 59.75 is Neutral, neither overbought nor oversold. The STOCH value of 66.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IRON.
Disc Medicine Risk Analysis
Disc Medicine disclosed 83 risk factors in its most recent earnings report. Disc Medicine reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Disc Medicine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $3.47B | -1,444.79 | -1.41% | ― | 95.29% | 98.21% | |
59 Neutral | $5.26B | -115.49 | -26.79% | ― | 96.03% | 82.27% | |
56 Neutral | $2.50B | -51.00 | -14.19% | ― | 128.99% | 58.46% | |
55 Neutral | $2.45B | -5.69 | -34.11% | ― | 78.34% | -161.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.89B | -2.97 | -54.32% | ― | 11.07% | 32.35% | |
50 Neutral | $2.93B | -11.53 | -36.95% | ― | ― | -68.57% |
* Healthcare Sector Average
IRON
Disc Medicine
76.59
18.85
32.65%
AGIO
Agios Pharma
41.23
2.00
5.10%
TVTX
Travere Therapeutics
56.59
39.68
234.65%
ARQT
Arcutis Biotherapeutics
27.74
11.84
74.47%
TARS
Tarsus Pharmaceuticals
58.14
16.61
40.00%
RXRX
Recursion Pharmaceuticals
3.56
-1.72
-32.58%
Disc Medicine Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Disc Medicine Amends Loan Agreement, Expands Debt Capacity
Positive
Jun 30, 2026
On June 25, 2026, Disc Medicine, Inc. amended its existing Loan and Security Agreement with Hercules Capital, Inc. to extend the periods during which it can draw future debt financing tranches. Under the amendment, the company agreed to immediatel...
Executive/Board ChangesShareholder Meetings
Disc Medicine Stockholders Approve Governance and Executive Pay
Positive
Jun 24, 2026
At its annual meeting of stockholders held on June 18, 2026, Disc Medicine, Inc. reported the election of three Class III directors, Donald Nicholson, Ph.D., John Quisel, J.D., Ph.D., and William White, M.P.P., J.D., to serve three-year terms endi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.